Grants for Public Housing Authorities

The purpose of this NOFO is to solicit applications for Guardrail Safety Training program that will result in the award of one (1) cooperative agreement award and the distribution of up to $500,000.00 in Federal funding over the life of the project. The actual amount available to be awarded under this notice will be subject to the availability of funds. PROGRAM GOALS The goal of Guardrail Safety Training is three-fold:1. To provide technical assistance;2. To develop support materials for training activities; and3. To develop and conduct webinar trainings for roadway agency standards engineers/sections.Through the development of the products outlined in this cooperative agreement the desired outcome is improved guardrail design and installation.ADMINISTRATION GOALSThe FHWA seeks to fund tasks under this NOFO that advance the United States Department of Transportations National Roadway Safety Strategy (NRSS). The NRSS outlines the Departments comprehensive approach to significantly reducing serious injuries and deaths on our Nations highways, roads, and streets. This is the first step in working toward an ambitious long-term goal of reaching zero roadway fatalities.

The WORC Initiative aims to fund grants that create economic mobility, address inequities for historically marginalized communities of color, rural areas, and other underserved and underrepresented communities. These grants are designed to produce high-quality employment outcomes for workers in the Appalachian, Delta, and Northern Border regions, enabling them to remain and thrive in their communities. The Initiative provides grant funds to help impacted communities develop local and regional workforce development solutions aligned with existing economic development strategies and community partnerships, promoting new, sustainable job opportunities and long-term economic vitality with a focus on equity and underserved populations. WORC Round 6 places a strong emphasis on three key focus areas: enhancing access to Good Jobs, prioritizing equity, and sustaining impact. Questions regarding this Funding Opportunity Announcement (FOA) Forecast may be emailed to DOL-ETA-DWG@dol.gov; however, please note there is limited information that may be shared with the public, as this FOA is currently under development. We encourage prospective applicants and interested parties to use the Grants.gov subscription option to register for future updates provided for this particular FOA.

The purpose of this Notice of Funding Opportunity (NOFO) is to support collaborative, transdisciplinary, translational research projects which advance exceptionally promising, chemically complex botanical and other natural products relevant to dietary supplements towards highly informative clinical trials of their effects on quantitative, objective measures of human resilience. Dynamic, synergistic interactions among the range of experts required to ensure rigor in all aspects of this research will be supported by a multi-PD/PI team collaborating on a single set of integrated specific aims, culminating in data on optimal parameters for a future proposed clinical efficacy trial, as well as the development and validation of other critical knowledge and methods for interpretation of such a trial, such as clinical assessment of the engagement of an outcome-relevant target. Enhancing workforce and institutional capacity to conduct future rigorous, transdisciplinary research on chemically complex natural products must be built into the plans for research and for enhancing diverse perspectives. Achievement of the RM1 specific aims is expected to provide a strong foundation for a future highly informative clinical efficacy trial of the effects on resilience of a chemically complex natural product.This NOFO is one component of the Consortium Advancing Research on Botanicals and Other Natural Products (CARBON) Program. Other components of this Program include RFA-AT-24-008, Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01) and RFA-AT-24-007, Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data (R24).

This grant provides funding for researchers to explore the complex interactions between the brain and immune system in the context of HIV and substance use disorders, aiming to identify new therapeutic targets and improve understanding of related neurological issues.

The National Center for Complementary and Integrative Health (NCCIH) with the Office of Dietary Supplements (ODS) solicit limited applications for continuation of an established nuclear magnetic resonance (NMR) research resource consisting of raw and meta-data from natural products ranging from crude extracts to purified substances; with the capacity to upload, download, store, search and analyze raw NMR data. The purpose of this limited competition is to promote sustainability, scaling and wider community inclusiveness of the established NMR research resource. This notice of funding opportunity (NOFO) is part of the Consortium Advancing Research on Botanicals and Other Natural Products (CARBON) Program. Other components of this Program include the Botanical Dietary Supplements Translational Research Teams (RM1) and Leveraging Big Data to Understand Natural Product Impacts on Whole Person Health (R01).

This grant provides funding for researchers to explore the interactions between the brain and immune system in the context of HIV and substance use disorders, aiming to identify new therapeutic targets and improve understanding of related neurological issues.

Notice of Funding Opportunity Description Background The Food and Drug Administration (FDA) protects the public health by ensuring that medical products intended to be marketed in the United States are safe and effective for their intended use. FDA stakeholders are exploring innovative ways to produce scientific evidence in support of regulatory submissions, including the development of new data sources, study designs, methodologies, and technologies. FDA encourages and facilitates the use of such innovative approaches while ensuring that the scientific evidence supporting marketing approvals meet our high evidentiary standards. The Prescription Drug User Fee Act VII (PDUFA VII) commitment letter represents the product of discussions between the FDA, regulated industry, and public stakeholders, as mandated by Congress. The performance and procedural goals and other commitments specified in the PDUFA VII commitment letter apply to aspects of the human drug review program that are important for facilitating timely access to safe, effective, and innovative new medicines for patients. The commitment letter includes goals relating to the use of digital health technologies (DHTs) to support drug development and review. A DHT is a system that uses computing platforms, connectivity, software, and/or sensors, for health care and related uses. DHTs for remote data acquisition in clinical investigations can include hardware and/or software to perform one or more functions. DHTs may rely on or work with other technologies that support their operation, such as general-purpose computing platforms (e.g., smartphones) and communication networks. Among other activities relating to the use of DHTs, FDA has established a Framework for the Use of DHTs in Drug and Biological Product Development to guide the use of DHT-derived data in regulatory decision-making for drugs (hereinafter Framework ). The Framework highlights FDA’s DHT efforts including workshops and demonstration projects; engagement with stakeholders; establishment of internal processes to support the evaluation of DHTs for use in drug development; promotion of shared learning and consistency regarding DHT-based policy, procedure, and analytic tool development; and publication of guidance documents. In addition, FDA’s webpage DHTs for Drug Development (available at: https://www.fda.gov/science-research/science-and-research-special-topics/digital-health-technologies-dhts-drug-development) provides an overview of the ongoing DHT efforts, including demonstration projects. A variety of project types are welcomed under this NOFO, applicable to drugs and biologics (not devices). FDA is particularly interested in projects that evaluate the use of DHTs in drug development. Project Objectives The overarching goal of this notice of funding opportunity (NOFO) is to explore the role of DHTs (e.g., actigraphy, photography, environmental sensors) in the evaluation of new drugs. These projects may involve engagement with researchers from academia, the biopharmaceutical industry, patient groups, and other stakeholders. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. The scope includes, but is not limited to, projects that focus on: Comparing digital measurements to traditional measurements in clinical trials to evaluate drugs Developing and evaluating novel endpoints using DHTs to address unmet needs for drug clinical trials (e.g., use of environmental sensors to capture apnea in pediatric patients) Comparing metrics to evaluate continuous measurements (e.g., maximum activity and stamina) Capturing early manifestations of chronic diseases (e.g., dementia) through the use of DHTs

Notice of Funding Opportunity Description Background The accumulation of misprocessed and aberrant proteins is a defining characteristic of various neurodegenerative conditions, such as AD and frontotemporal lobar degeneration (FTLD). These atypical proteins may arise from various factors, such as somatic mutations, environmental changes, genomic instability, irregular RNA processing, and proteolytic cleavages, as well as incorrect folding and post-translational modifications. For instance, many recent proteome and transcriptome profiling of AD brains reveals RNA splicing dysfunction and abnormal accumulation of U1 small nuclear ribonucleoprotein (snRNP) and transactive response DNA-binding protein 43 (TDP-43). In AD, U1-70K and its N-terminal 40-KDa fragment (N40K) is one of the most abundant proteins in the insoluble fraction of cell lysates. TDP-43 is an RNA-binding protein. In AD, TDP-43 pathology is observed in approximately 25-50% of cases, particularly in cases with co-morbidities such as Lewy body dementia or hippocampal sclerosis. However, the relationship between U1snRNP/TDP-43 and AD pathology is complex and not fully understood. The disruption of RNA processing is thought to be one possible mechanism to cause the accumulation of misprocessed proteins, which can lead to altered expression of genes involved in AD pathology, including amyloid precursor protein (APP), tau, and synaptic proteins. Understanding the mechanisms underlying the dysregulation of misprocessed proteins in neurodegenerative diseases will be important for developing effective therapies. Approaches that target the production or aggregation of misprocessed proteins, or that promote their clearance or degradation, may be effective in preventing or slowing disease progression. Purpose This NOFO invites innovative research proposals to explore the accumulation of misprocessed proteins in Tauopathies within specific brain regions and cell types. This NOFO encourages collaborative efforts to create advanced single-cell or single-cell type proteogenomic platforms. These platforms aim to shed light on dynamic changes in protein-misfolding responses in neuronal proteomes and their potential biological consequences during aging and the development of AD/ADRD. Research Objectives This NOFO aims to provide a proof-of-principal for a novel strategy to identify misprocessed and aberrant proteins in Tau diseases using the proteogenomic approach. Proteogenomics is an integrated approach that combines proteomics and genomics data. In proteogenomics, genomic and transcriptomic experiments are more closely integrated to identify potential protein coding and non-coding regions in the genome. These regions are then validated using mass spectrometry-based proteomics. Proteogenomics has emerged as a powerful tool for investigating the role of protein homeostasis in AD pathogenesis, especially in the context of mis-translated and mis-repaired proteins. However, relying solely on misprocessed protein levels to draw conclusions about biological processes is unlikely to be reliable. Therefore, an intermediate layer of functional validation is essential to transform proteogeomic data into meaningful biological information. As a result, the objective of this NOFO is not only to confirm changes in protein abundance using other methods, but also to assess the biological effects of those changes in some model systems, especially in the area of tauopathies, to ensure high interlaboratory reproducibility. Using the proteogenomics approach, this NOFO aims to accomplish the following: Create a comprehensive database of misprocessed and aberrant proteins in selected mouse models of human Tau diseases. Cross-validate the presence of misprocessed and aberrant proteins in human AD/ADRD brains. Identify new molecular pathways and novel misprocessed protein-protein interaction networks that are not currently in most datasets. Define novel mechanisms through which misprocessed and aberrant proteins influence the onset and progression of neurodegeneration in tauopathies. Identify disease specific therapeutic targets in neurodegenerative diseases. It is expected that applications responding to this initiative will use the latest cell-type-specific labeling and proteogenomic techniques with suitable model systems to understand the etiology of tauopathies in aging and AD.

The specific purpose of this NOFO is to promote the development of a diverse, interdisciplinary workforce needed to conduct translational research on Alzheimer's disease and Alzheimer's-related dementias from target discovery through clinical development. This NOFO will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e., basic biology, translational and clinical research, data science). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, behavioral research, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational, and clinical research for AD/ADRD.

This funding opportunity provides financial support for research facilities to acquire modern equipment that measures environmental factors affecting animal research, enhancing the reliability and reproducibility of scientific studies.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the establishment of one (1) Center of Excellence (CoE) to coordinate the research community of infectious and immune-mediated disease (IID) computational modelers and advance IID modeling research across biological scales. The CoE must include three (3) coordinating cores and two (2) research projects to advance and integrate bridge models across scales in the context of IID, including HIV/AIDS. The CoE will accelerate multi-scale model development, sharing and re-use, and support collaboration to benefit the entire IID research community.

This grant provides funding for institutional research training programs to develop skilled neuroscientists through comprehensive training in research, statistics, and communication, specifically targeting advanced graduate students and postdoctoral fellows.

The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDCR UE5 program is to support educational activities that enhance the diversity of the biomedical, behavioral, and clinical dental, oral, and craniofacial (DOC) research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Mentoring Activities Courses for Skills Development The major goal of this funding opportunity is to establish a mentoring network and grant writing skills that will facilitate a diverse pool of early career investigators, including those from groups underrepresented in biomedical, behavioral, and clinical research (see NOT-OD-20-031), to advance their research careers and transition to independent research careers. This funding opportunity invites applications from senior faculty, experienced mentors and experienced researchers of higher education institutions and professional societies and organizations with existing federally funded programs to develop and direct a mentoring network for eligible early career investigators (post doctorates and junior faculty). Proposed programs are expected to contribute to the development of a skilled cadre of investigators in requisite scientific research areas to advance the objectives of the NIDCR Strategic Plan.

CDC anticipates an Approximate Total Fiscal Year Funding amount of $3,900,000 for Year 1 for 2 awards, subject to the availability of funds. This NOFO will support organizations that engage state, tribal, local, and territorial immunization programs funded through CDC;apos;s Immunization and Vaccines for Children program to advance systems supporting program delivery, improve data quality, and improve vaccination coverage. The intent of this NOFO is to achieve impactful and sustainable outcomes that require implementation of strategies to:Advance technology and standards for immunization Engage and support the immunization community in efforts to assess and monitor vaccine coverage, identify populations at risk, and respond to vaccine-preventable disease outbreaksImprove immunization data collection and useEducate and develop the public health immunization workforcePotential projects include those that support the strategies listed above such as: Consistent implementation of immunization information system (IIS) standardsSupporting jurisdictions;apos; ability to leverage the CDC Immunization Gateway to facilitate data exchange and improve interoperabilityImplement communication and engagement with the public health immunization community through regular communications, supporting user groups, and providing technical assistanceSupport IIS leadership development through competency development, standard role descriptions, competency based training, etc.

Notice of Funding Opportunity SummaryNRCS is announcing the availability of Conservation Innovation Grants (CIG) Caribbean Area Program funding to stimulate the development and adoption of innovative conservation approaches and technologies. Applications are accepted from eligible entities (Section C) for projects carried out in the Caribbean Area (Puerto Rico (PR) and the U.S. Virgin Islands (USVI)). A total of up to $500,000 is available for the Caribbean Area CIG competition in FY 2024. All non-Foreign, non-federal entities (NFE) and individuals are invited to apply, with the sole exception of federal agencies. Projects may be between one and three years in duration. The maximum award amount for a single award in FY 2024 is $100,000. For new users of Grants.gov, see Section D. of the full Notice of Funding Opportunity for information about steps required before submitting an application via Grants.gov. Completing all steps required to start an application can take a significant amount of time, plan accordingly.Key DatesApplicants must submit their applications via Grants.gov by 11:59 pm Eastern Time on May 15, 2024 For technical issues with Grants.gov, contact Grants.gov Applicant Support at 1-800-518-4726 or support@grants.gov. Awarding agency staff cannot support applicants regarding Grants.gov accounts. For inquiries specific to the content of the NFO requirements, contact the federal awarding agency contact (section G of this NFO). Please limit questions to those regarding specific information contained in this NFO (such as dates, page numbers, clarification of discrepancies, etc.). Questions related to eligibility, or the merits of a specific proposal will not be addressed.A webinar for CIG applicants is scheduled for April 9, 2024 at 9 a.m. Atlantic Standard Time. Information on how to participate in the webinar will be posted to the HYPERLINK website. Applicants are encouraged to visit the Caribbean Area CIG website to learn more about the CIG program.The agency anticipates making selections by June 30, 2024 and expects to execute awards by July 30, 2024. These dates are estimates and are subject to change.

The purpose of this funding opportunity is to support projects which enhance the quality, effectiveness and proven outcomes of nutrition services programs within the aging services network. The Older Americans Act (OAA) provides funding to States and Tribal Organizations to support a broad array of services that enable older adults to remain in their homes and communities and assist family and informal caregivers to care for their loved ones for as long as possible. More information is located here: https://acl.gov/programs/health-wellness/nutrition-services. Through this program, funds will be used to foster the development, testing and replication of innovative service delivery models, policies and partnerships that improve collaboration and coordination between OAA nutrition programs and multi-purpose senior centers. Projects proposed under this grant program must have the potential for broad implementation throughout the aging services network.

With this solicitation, NIJ seeks proposals for rigorous research and evaluation projects that inform policy and practice in the field of youth justice and delinquency prevention. Specifically, this solicitation seeks proposals for studies that advance knowledge and understanding in the following two categories: 1. Youth Justice Reinvestment Studies which evaluate the effectiveness, including cost-effectiveness, of youth justice system reforms and subsequent reinvestments into programs that serve youth in their communities. 2. Prevention and Intervention Program Effectiveness Studies which evaluate the effectiveness of school and community-based prevention and intervention programs.

This program provides funding to establish community-based telehealth resources that connect rural veterans with healthcare providers, improving their access to essential medical services.

This grant provides funding for innovative research projects aimed at improving the diagnosis and treatment of health conditions related to the September 11 attacks, specifically targeting first responders and survivors affected by these events.

The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.